Cargando…
Atezolizumab plus anthracycline-based chemotherapy in metastatic triple-negative breast cancer: the randomized, double-blind phase 2b ALICE trial
Immune checkpoint inhibitors have shown efficacy against metastatic triple-negative breast cancer (mTNBC) but only for PD-L1(positive) disease. The randomized, placebo-controlled ALICE trial (NCT03164993) evaluated the addition of atezolizumab (anti-PD-L1) to immune-stimulating chemotherapy in mTNBC...
Autores principales: | Røssevold, Andreas Hagen, Andresen, Nikolai Kragøe, Bjerre, Christina Annette, Gilje, Bjørnar, Jakobsen, Erik Hugger, Raj, Sunil Xavier, Falk, Ragnhild Sørum, Russnes, Hege Giercksky, Jahr, Thea, Mathiesen, Randi Ruud, Lømo, Jon, Garred, Øystein, Chauhan, Sudhir Kumar, Lereim, Ragnhild Reehorst, Dunn, Claire, Naume, Bjørn, Kyte, Jon Amund |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group US
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9800277/ https://www.ncbi.nlm.nih.gov/pubmed/36482103 http://dx.doi.org/10.1038/s41591-022-02126-1 |
Ejemplares similares
-
ALICE: a randomized placebo-controlled phase II study evaluating atezolizumab combined with immunogenic chemotherapy in patients with metastatic triple-negative breast cancer
por: Kyte, J. A., et al.
Publicado: (2020) -
Development of robust targeted proteomics assays for cerebrospinal fluid biomarkers in multiple sclerosis
por: Guldbrandsen, Astrid, et al.
Publicado: (2020) -
An independent poor-prognosis subtype of breast cancer defined by a distinct tumor immune microenvironment
por: Tekpli, Xavier, et al.
Publicado: (2019) -
The Brain Proteome of the Ubiquitin Ligase Peli1 Knock-Out Mouse during Experimental Autoimmune Encephalomyelitis
por: Lereim, Ragnhild Reehorst, et al.
Publicado: (2016) -
Strategies for Improving the Efficacy of CAR T Cells in Solid Cancers
por: Kyte, Jon Amund
Publicado: (2022)